Document is current
Any future updates will be listed below
-
Authors
Fumagalli, Carlo https://orcid.org/0000-0001-7963-5049
Cappelli, Francesco https://orcid.org/0000-0001-7237-1714
Maurer, Mathew S. https://orcid.org/0000-0001-5400-5008
aus dem Siepen, Fabian https://orcid.org/0000-0003-4264-1722
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
Garcia-Pavia, Pablo https://orcid.org/0000-0002-5470-2257
Hanna, Mazen https://orcid.org/0000-0002-7251-3003
Carlsson, Martin https://orcid.org/0000-0003-3106-0754
Damy, Thibaud https://orcid.org/0000-0003-4058-3848
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02791230 at ClinicalTrials.govnct00628745 at ClinicalTrials.govDocuments that mention this clinical trial
Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
https://doi.org/10.1007/s40119-026-00474-4
Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension
https://doi.org/10.1007/s40119-026-00470-8
Documents that mention this clinical trial
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40120-021-00267-y
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology
https://doi.org/10.1185/03007995.2012.754349
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS
https://doi.org/10.1007/s40119-025-00421-9
Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
https://doi.org/10.1007/s40119-026-00474-4
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40119-023-00344-3
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
https://doi.org/10.1007/s40119-022-00265-7
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy
https://doi.org/10.1080/13506129.2019.1643714
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
https://doi.org/10.1185/03007995.2012.754348
Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
https://doi.org/10.1007/s40119-021-00226-6
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 1 June 2026
Accepted: 18 August 2026
First Online: 11 September 2026
Declarations
Conflict of Interest: Carlo Fumagalli reports no conflict of interest. Francesco Cappelli reports honoraria for advisory board participation from Alnylam, AstraZeneca, Bayer, BridgeBio, Bristol Myers Squibb, Novo Nordisk, and Pfizer; and unconditional research grants from Pfizer. Mathew S. Maurer reports grants and personal fees from Akcea, Alnylam, Eidos, GlaxoSmithKline, Pfizer, Prothena, and Ionis. Fabian aus dem Siepen reports speaker fees from Alnylam, Bayer, Janssen, and Pfizer; and consulting fees from Bayer and Pfizer. Angela Dispenzieri reports research grants from AbbVie, Alnylam, Celgene, Janssen, Takeda, and Pfizer. Pablo Garcia-Pavia reports speaking fees from Alnylam, AstraZeneca, BridgeBio, Intellia, Ionis, Novo Nordisk, Intellia, and Pfizer; consulting fees from Akcea, Alexion, Alnylam, AstraZeneca, Attralus, Bayer, BridgeBio, General Electric, Intellia, Neurimmune, Novo Nordisk, and Pfizer; and research/educational support to his institution from Alnylam, AstraZeneca, BridgeBio, Intellia, Novo Nordisk, and Pfizer. Martin Carlsson is an employee of and owns stock/options in Pfizer. Mazen Hanna has attended advisory boards for Alexion, Alnylam, Eidos, Ionis, and Pfizer. Thibaud Damy reports consulting fees from Alnylam, GlaxoSmithKline, Pfizer, and Prothena; honoraria from Alnylam, Pfizer, and Prothena; research grants from GlaxoSmithKline, and Pfizer; and clinical trial support from Alnylam, Ionis, and Pfizer.
Ethical Approval: All study sites received ethical or institutional review board approval before patient enrollment. All patients provided written informed consent. Both studies followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki.
